Company Profile

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).

Employees

Sector

Pharmaceuticals

More about the company

14/02/24	Aspen Neuroscience, Inc. Appoints Lisa Johnson-Pratt as Senior Vice President, Therapeutic Program Lead	CI
19/01/21	Mersana Therapeutics, Inc. Announces Carla Poulson as Chief Human Resources Officer	CI
09/11/20	Akcea Therapeutics Announces Scottish Medicines Consortium Enabled Access to Volanesorsen on the National Health Service in Scotland for the Treatment of Familial Chylomicronaemia Syndrome	CI
13/10/20	Akcea Therapeutics, Inc. Announces Management Changes	CI
12/10/20	Akcea Therapeutics, Inc.(NasdaqGS:AKCA) dropped from S&P TMI Index	CI
12/10/20	Akcea Therapeutics, Inc.(NasdaqGS:AKCA) dropped from S&P Global BMI Index	CI
12/10/20	Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell Small Cap Comp Value Index	CI
12/10/20	Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2000 Value Index	CI
12/10/20	Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2500 Value Index	CI
12/10/20	Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 3000 Value Index	CI
12/10/20	Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2000 Value-Dynamic Index	CI
12/10/20	Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2500 Growth-Dynamic Index	CI
12/10/20	Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2500 Value-Dynamic Index	CI

10/11/20	Ionis Pharmaceuticals : Akcea Therapeutics - WAYLIVRA, the first and only therapy for familial chylomicronaemia syndrome, to be available on the NHS in Scotland	AQ
09/11/20	Ionis Pharmaceuticals : and Akcea Recognize FCS Awareness Day with Global Community Efforts to Celebrate Unsung Heroes	AQ
04/11/20	IONIS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
04/11/20	Ionis Pharmaceuticals : and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen	AQ
02/11/20	Ionis Pharmaceuticals : and Akcea win prestigious Prix Galien Award for TEGSEDI as Best Biotechnology Product	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
AKCEA THERAPEUTICS, INC.	+0.17%	+0.17%	-	-	1.85B
ELI LILLY AND COMPANY	-0.38%	+1.08%	+22.72%	+215.48%	926B
JOHNSON & JOHNSON	-0.05%	+2.09%	+55.83%	+51.71%	586B
ABBVIE INC.	+0.59%	+4.68%	+20.73%	+53.90%	412B
ROCHE HOLDING AG	+2.16%	+5.16%	+25.45%	+32.23%	382B
ASTRAZENECA PLC	+2.39%	+9.59%	+32.51%	+35.14%	326B
NOVARTIS AG	+1.52%	+6.10%	+34.09%	+59.90%	317B
MERCK & CO., INC.	+0.13%	+3.77%	+46.45%	+11.00%	302B
NOVO NORDISK A/S	+0.73%	-1.60%	-45.57%	-37.14%	218B
AMGEN INC.	+1.13%	+2.39%	+28.23%	+55.22%	201B
Average	+0.84%	+3.16%	+24.49%	+53.05%	407.69B
Weighted average by Cap.	+0.65%	+2.94%	+28.12%	+82.04%

Akcea Therapeutics, Inc. Share Price

Equities

AKCA

US00972L1070

Pharmaceuticals

Latest news: Akcea Therapeutics, Inc.

Press Releases: Akcea Therapeutics, Inc.

Quotes and Performance

Managers and Directors: Akcea Therapeutics, Inc.

Other Pharmaceuticals

Company Profile